(Source: iCo Therapeutics Inc) November 24, 2015, Vancouver, Canada - iCo Therapeutics ('iCo' or 'the Company') (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ('IFRS'). 'As we continue to progress our oral delivery platform for Amp B we've also seen iCo-008 value building via our partner progressing systemic use indications, including a recently announced IND in the United States' said Andrew Rae, President & CEO of iCo Therapeutics. 'These advancements regarding iCo-008 are not only value enriching for...
↧
